

Supplementary Table S5 Change from baseline in 6-minute walk distance at Week 26

	Placebo			Selexipag			Treatment effect m (95% CI)*
	N	Median at baseline m (Q1, Q3)	Median change m (Q1, Q3)	N	Median at baseline m (Q1, Q3)	Median change m (Q1, Q3)	
PAH-CTD	167	359 (275, 401)	-10 (-199, 17)	167	370 (307, 408)	-2 (-100, 27)	12 (-4, 27)
PAH-SSc	93	338 (268, 387)	-22 (-230, 8)	77	360 (291, 400)	-13 (-93, 23)	15 (-8, 42)
PAH-SLE	37	397 (337, 420)	1 (-100, 21)	45	391 (360, 414)	16 (-10, 35)	17 (-8, 44)
PAH- MCTD/ CTD-other	37	369 (263, 399)	-2 (-167, 30)	45	360 (310, 401)	-9 (-240, 23)	-11 (-45, 23)

*Point estimate for location shift as estimated by Hodges-Lehmann method; missing 6-minute walk distance values were imputed according to a worst-case scenario as described previously [10].

CTD: connective tissue disease; MCTD: mixed connective tissue disease; PAH: pulmonary arterial hypertension; SLE: systemic lupus erythematosus; SSc: systemic sclerosis.